Join
Live feed
·
PRReleasevia Quantisnow
Axcella Health Inc. logo

Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH)

ByQuantisnow·Wall Street's wire, on your screen.
AXLA· Axcella Health Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AXLA (Axcella Health Inc.) and more on Quantisnow.